Norepinephrine Infusion Combined With Goal-directed Fluid Therapy in Patients Undergoing Kidney Transplantations

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorRenJi Hospital

About this trial

Delayed graft function (DGF), delineated by the necessity for dialytic intervention within the initial week post-transplantation, afflicts approximately 20%-50% of recipients. The primary objective of this study is to investigate the potential efficacy of norepinephrine infusion in conjunction with goal-directed fluid therapy (GDFT) in mitigating the occurrence of DGF among individuals undergoing kidney transplantations. The findings of this investigation have the potential to advance the field of perioperative care in kidney transplantations by providing insights into optimized management strategies.

Eligibility criteria

Qualifiers

Recipients aged 18 years or older

Scheduled to undergo kidney transplantations under general anesthesia

Cadaveric kidney transplantations

Sign the informed consent form

Disqualifiers

Donors aged under 18 years

Donor kidneys classified as Maastricht category I or II

Contraindications to radial artery catheterization

Pregnancy

Trial design

Treatments tested in this trial

  • Goal-Directed Fluid Therapy (GDFT)
  • Regular Fluid Therapy

Treatment groups

380 Participants
are divided into 2 treatment groups

Sponsors and collaborators